Other equities research analysts have also issued reports about the company. Zacks Investment Research upgraded Flagstar Bancorp from a hold rating to a buy rating and set a $38.00 price objective for the company in a research note on Monday, July 8th. HC Wainwright reiterated a neutral rating on shares of Aerpio Pharmaceuticals in a research note on Wednesday, June 12th.
Shares of Advaxis stock opened at $1.27 on Thursday. Advaxis has a twelve month low of $1.21 and a twelve month high of $24.60. The company has a 50-day simple moving average of $2.15.
Large investors have recently bought and sold shares of the business. Two Sigma Investments LP increased its stake in Advaxis by 2,468.2% during the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after buying an additional 355,415 shares in the last quarter. BlackRock Inc. increased its stake in Advaxis by 3.1% during the 4th quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock worth $275,000 after buying an additional 43,368 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in Advaxis by 5,970.3% during the 4th quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after buying an additional 553,031 shares in the last quarter. Institutional investors own 24.40% of the company’s stock.
Advaxis Company Profile
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
See Also: Trading Ex-Dividend Strategy
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.